Select publications

Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

Benson AB III et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22(16):3408-19. Abstract

Cassidy J et al. Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for Dukes’ C colon cancer: No differences in treatment arms that could influence survival outcome. Proc ASCO 2005;Abstract 3586.

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. Proc ASCO 2004;Abstract 3509.

Chau I et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16(4):549-57. Abstract

de Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003;Abstract 1015.

de Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO 2005;Abstract 3501.

Diaz-Rubio Garcia E et al. A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. Clin Transl Oncol 2005;7(1):3-11. Abstract

Giantonio BJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO GI Cancers Symposium 2005;Abstract 169a.

Gray RG et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc ASCO 2004;Abstract 3501.

Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 2005;5(Suppl 1):11-8. Abstract

O’Connell MJ et al. Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10- year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03. Proc ASCO 2005;Abstract 3511.

Poplin EA et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23(9):1819-25. Abstract

Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Endpoints for Colon Adjuvant Clinical Trials (CACT): Recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials. Proc ASCO 2005;Abstract 3512.

Schmoll HJ et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc ASCO 2005;Abstract 3523.

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005;Abstract 3521.

van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract